002630 — Orient Bio Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapNeutral

Annual cashflow statement for Orient Bio, fiscal year end - March 31st, KRW millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	34,198	-12,424	12,871	-13,195	-4,567
Depreciation
Amortisation
Non-Cash Items	-33,942	-4,384	-13,141	11,613	1,645
Discontinued Operations
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-1,830	14,878	1,343	380	3,314
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Other Operating Cash Flow
Cash from Operating Activities	2,351	1,160	3,757	752	2,596
Capital Expenditures	-2,211	-486	-925	-4,789	-2,050
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	18,981	-20,172	-2,191	5,104	-566
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	16,770	-20,658	-3,116	316	-2,616
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-1,134	-6,792	-570	-840	-689
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	19,052	-24,058	175	423	-700